Given
the
concerns
of
waning
immunity
from
primary
COVID-19
vaccines
and
first
booster
dose,
we
conducted
an
on-line
cross-sectional
study
in
May
2022
to
investigate
willingness
receive
a
second
dose
or
new
vaccine
its
associated
factors.
Overall,
22.7%
participants
were
willing
be
vaccinated,
39.3%
unsure,
but
tend
willing,
25.8%
4.9%
unwilling,
7.4%
unwilling
vaccinated.
The
main
reasons
against
accepting
COVID‐19
included
about
side
effects,
opinion
that
further
vaccination
is
unnecessary,
effectiveness
uncertainties.
Males,
younger
individuals,
without
previous
diagnosis,
those
with
good/very
good
self-perceived
physical
health
significantly
more
frequently
vaccine.
Also,
increased
fear
COVID-19,
trust
decreased
willingness.
Our
results
show
some
hesitancy
unwillingness
toward
indicate
affect
public
PLoS ONE,
Journal Year:
2022,
Volume and Issue:
17(7), P. e0271625 - e0271625
Published: July 20, 2022
Aims
This
study
surveyed
people
regarding
their
acceptance
of
periodic
doses
(i.e.,
annual
boosters)
the
COVID-19
vaccine.
Moreover,
factors
that
correlate
with
attitudes
toward
vaccines
were
assessed
and
identified.
Method
The
employed
a
cross-sectional
methodology.
questionnaire
was
distributed
using
Google
Forms.
Data
collected
during
last
quarter
2021,
1,416
adults
(18
years
old
over)
from
Jordan
responded.
Acceptance
vaccine
calculated
as
percentage
total
number
participants,
scored.
A
multiple
regression
model
used
to
determine
predictors
public
dose
vaccines.
Results
rate
for
receiving
low
(19.3%).
Additionally,
26%
participants
unsure
about
additional
However,
54.7%
had
negative
attitude
getting
doses.
mean
score
47.9
(range:
29–66).
Among
identified
leading
decisions
not
receive
side
effects
(49.1%),
waiting
further
clinical
studies
(38.8%),
perceived
no
risk
contracting
(17.7%).
Regression
analysis
showed
income,
educational
attainment,
following
news
participants’
Conclusion
in
is
low,
public’s
generally
negative.
Health
programs
interventions
are
needed
promote
positive
attitudes.
Vaccines,
Journal Year:
2023,
Volume and Issue:
11(5), P. 920 - 920
Published: April 29, 2023
Booster
vaccination
reduces
the
incidence
of
severe
cases
and
mortality
related
to
COVID-19,
with
cellular
immunity
playing
an
important
role.
However,
little
is
known
about
proportion
population
that
has
achieved
after
booster
vaccination.
Thus,
we
conducted
a
Fukushima
cohort
database
assessed
humoral
in
2526
residents
healthcare
workers
Prefecture
Japan
through
continuous
blood
collection
every
3
months
from
September
2021.
We
identified
people
induced
using
T-SPOT.COVID
test,
analyzed
their
background
characteristics.
Among
1089
participants,
64.3%
(700/1089)
had
reactive
Multivariable
analysis
revealed
following
independent
predictors
immunity:
age
<
40
years
(adjusted
odds
ratio:
1.81;
95%
confidence
interval:
1.19–2.75;
p-value:
0.005)
adverse
reactions
(1.92,
1.19–3.09,
0.007).
Notably,
despite
IgG(S)
neutralizing
antibody
titers
≥500
AU/mL,
33.9%
(349/1031)
33.5%
(341/1017)
respectively,
did
not
have
immunity.
In
summary,
this
first
study
evaluate
at
level
albeit
several
limitations.
Future
studies
will
need
previously
infected
subjects
T-cell
subsets.
Vaccines,
Journal Year:
2023,
Volume and Issue:
12(1), P. 34 - 34
Published: Dec. 28, 2023
Mass
vaccination
against
COVID-19
is
the
best
method
to
ensure
herd
immunity
in
order
curb
effect
of
pandemic
on
global
economy.
It
therefore
important
assess
determinants
vaccine
acceptance
and
hesitancy
a
scale.
Factors
were
recorded
from
cross-sectional
studies
analyzed
with
t-Test,
ANOVA,
correlation,
meta-regression
analyses
synthesized
identify
trends
inform
policy.
We
registered
protocol
(ID:
CRD42022350418)
used
standard
Cochrane
methods
PRISMA
guidelines
collect
synthesize
articles
published
between
January
2020
August
2023.
A
total
67
576
185
countries
involving
3081,766
participants
included
this
synthesis.
Global
was
65.27%
(95%
CI;
62.72–67.84%),
while
stood
at
32.1%
29.05–35.17%).
One-Way
ANOVA
showed
that
there
no
significant
difference
percentage
Gross
Domestic
Product
spent
procurement
across
World
Bank
income
levels
(p
<
0.187).
There
0.001)
0.005)
different
Income
levels.
level
had
strong
influence
0.0004)
0.003)
but
did
not.
correlation
(r
=
−0.11,
p
0.164)
or
−0.09,
0.234).
Meta-regression
analysis
living
an
urban
setting
(OR
4.83,
95%
0.67–212.8),
rural
2.53,
0.29–119.33),
older
1.98,
0.99–4.07),
higher
education
1.76,
0.85–3.81),
being
low
earner
2.85,
0.45–30.63)
increased
odds
high
acceptance.
influenza
33.06,
5.03–1395.01),
mistrust
for
vaccines
3.91,
1.92–8.24),
complacency
2.86,
1.02–8.83),
pregnancy
2.3,
0.12–141.76),
taking
traditional
herbs
2.15,
0.52–10.42),
female
1.53,
0.78–3.01),
safety
concerns
1.29,
0.67–2.51).
proposed
number
recommendations
increase
COVID-19.
Given
the
concerns
of
waning
immunity
from
primary
COVID-19
vaccines
and
first
booster
dose,
we
conducted
an
on-line
cross-sectional
study
in
May
2022
to
investigate
willingness
receive
a
second
dose
or
new
vaccine
its
associated
factors.
Overall,
22.7%
participants
were
willing
be
vaccinated,
39.3%
unsure,
but
tend
willing,
25.8%
4.9%
unwilling,
7.4%
unwilling
vaccinated.
The
main
reasons
against
accepting
COVID‐19
included
about
side
effects,
opinion
that
further
vaccination
is
unnecessary,
effectiveness
uncertainties.
Males,
younger
individuals,
without
previous
diagnosis,
those
with
good/very
good
self-perceived
physical
health
significantly
more
frequently
vaccine.
Also,
increased
fear
COVID-19,
trust
decreased
willingness.
Our
results
show
some
hesitancy
unwillingness
toward
indicate
affect
public
